| Psoriasis vulgaris
Skyrizi vs Bryhali
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Skyrizi vs Bryhali with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBryhali has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bryhali but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Bryhali
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
Topical
Daily
Topical corticosteroid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
—
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Bryhali
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Bryhali
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Bryhali
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Bryhali.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
BryhaliView full Bryhali profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.